.
Science Daily : Hormone Disorders
Hormone Disorders News -- ScienceDaily
Read the latest research on endocrinology. Learn about hormone disorders, new hormone treatment options, hormone therapy and more.

Hormone Disorders News -- ScienceDaily
  • High-normal thyroid hormone level in pregnancy may affect fetal brain development
    A new study finds that not only low but also high maternal thyroid hormone levels during early pregnancy may significantly lower the infant's IQ later in childhood. The study results suggest that the common practice of treating pregnant women who have mild thyroid hormone deficiency may pose unexpected risks to the developing baby's brain.

  • When I'm 64 -- I'll still have hot flashes?
    Some 40 percent of women 60 to 65 years old still have hot flashes. For many, the hot flashes are occasional and mild, but for some, they remain really troublesome. Sexual symptoms also remain a problem for more than half these older women. Furthermore, women bothered by these symptoms are often not getting treatment, even though treatments are available, experts say.

  • Exposure to endocrine-disrupting chemicals costs EU billions annually
    Human exposure to endocrine-disrupting chemicals (EDCs) likely contributes to a number of diseases and health conditions in the EU, with costs estimated between €150-260 billion per year (1.2-2.0% of Gross Domestic Product), according to a new series of studies.

  • Hormone therapy in transgender adults safe, study shows
    In the most comprehensive review to date addressing the relative safety of hormone therapy for transgender persons, researchers have found that hormone therapy in transgender adults is safe. The findings may help reduce the barriers for transgender individuals to receive medical care.

  • Androgen receptor abnormality may not be associated with primary resistance to taxane chemotherapy
    Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Treatment outcomes were largely similar for the 17 patients with AR-V7-positive prostate cancer and the 20 patients with AR-V7-negative disease included in this analysis.

The Canary Club is an educational advisory group with a team of medical advisors headed by Richard Shames, M.D.